 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
13 News |  |
- | hexameric CD95 ligand (APO010) / Oncology Venture
Preclinical, Journal, IO Biomarker: Characterization of resistance to a recombinant hexameric Fas-ligand (APO010) in human cancer cell lines. (Pubmed Central) - Dec 16, 2020
No abstract available
- | hexameric CD95 ligand (APO010) / Allarity Therap
Enrollment change, Trial termination: Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP (clinicaltrials.gov) - Jan 30, 2020
P1/2, N=1, Terminated, Sponsor: Oncology Venture
No abstract available N=35 --> 1 | Recruiting --> Terminated; The study was terminated early due to sponsors decision
- | ApoGraft (allogeneic mobilised peripheral blood cells) / Cellect Biotechnology
Trial completion date, Trial primary completion date: Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation (clinicaltrials.gov) - Jul 29, 2019
P1/2, N=12, Recruiting, Sponsor: Cellect Biotechnology
N=35 --> 1 | Recruiting --> Terminated; The study was terminated early due to sponsors decision Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Dec 2019 --> Jul 2020
- | hexameric CD95 ligand (APO010) / Allarity Therap
Trial completion date, Trial primary completion date: Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP (clinicaltrials.gov) - Feb 8, 2019
P1/2, N=35, Recruiting, Sponsor: Oncology Venture
Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Dec 2019 --> Jul 2020 Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
- | ApoGraft (allogeneic mobilised peripheral blood cells) / Cellect Biotechnology
Trial completion date, Trial primary completion date: Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation (clinicaltrials.gov) - Jun 6, 2018
P1/2, N=12, Recruiting, Sponsor: Cellect Biotechnology
Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Sep 2018 --> Dec 2019 | Trial primary completion date: Feb 2018 --> Dec 2019
- | hexameric CD95 ligand (APO010) / Allarity Therap
Trial completion date, Trial primary completion date: Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP (clinicaltrials.gov) - Jun 6, 2018
P1/2, N=35, Recruiting, Sponsor: Oncology Venture
Trial completion date: Sep 2018 --> Dec 2019 | Trial primary completion date: Feb 2018 --> Dec 2019 Trial completion date: Sep 2018 --> Jan 2019 | Trial primary completion date: May 2018 --> Dec 2018
- | ApoGraft (allogeneic mobilised peripheral blood cells) / Cellect Biotechnology
Enrollment open, Trial initiation date, Trial primary completion date: Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation (clinicaltrials.gov) - Jan 10, 2017
P1/2, N=12, Recruiting, Sponsor: Cellect Biotechnology
Trial completion date: Sep 2018 --> Jan 2019 | Trial primary completion date: May 2018 --> Dec 2018 Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Jan 2017 | Trial primary completion date: Aug 2017 --> Feb 2018
- ApoGraft (allogeneic mobilised peripheral blood cells) / Cellect Biotechnology
New P1/2 trial: Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation (clinicaltrials.gov) - Jul 12, 2016
P1/2, N=12, Not yet recruiting, Sponsor: Cellect Biotechnology
- hexameric CD95 ligand (APO010) / Allarity Therap
Enrollment change: AP1001: A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors (clinicaltrials.gov) - Nov 4, 2012
P1, N=26, Completed, Sponsor: TopoTarget A/S
Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Jan 2017 | Trial primary completion date: Aug 2017 --> Feb 2018 N=35 --> 26
- | hexameric CD95 ligand (APO010) / Allarity Therap
Trial completion: AP1001: A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors (clinicaltrials.gov) - Nov 4, 2012
P1, N=26, Completed, Sponsor: TopoTarget A/S
N=35 --> 26 Recruiting --> Completed